Gyre Therapeutics Inc. (GYRE)vsRegeneron Pharmaceuticals Inc (REGN)
GYRE
Gyre Therapeutics Inc.
$7.18
+3.46%
HEALTHCARE · Cap: $647.36M
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 12202% more annual revenue ($14.34B vs $116.59M). REGN leads profitability with a 31.4% profit margin vs 4.3%. REGN trades at a lower P/E of 17.9x. REGN earns a higher WallStSmart Score of 58/100 (C).
GYRE
Hold39
out of 100
Grade: F
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-735.1%
Fair Value
$0.94
Current Price
$7.18
$6.24 premium
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 33.4% year-over-year
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
1.7% earnings growth
Smaller company, higher risk/reward
4.3% margin — thin
Operating margin of 0.3%
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : GYRE
The strongest argument for GYRE centers on Revenue Growth. Revenue growth of 33.4% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : GYRE
The primary concerns for GYRE are EPS Growth, Market Cap, Profit Margin. A P/E of 336.0x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GYRE profiles as a hypergrowth stock while REGN is a value play — different risk/reward profiles.
GYRE carries more volatility with a beta of 6.92 — expect wider price swings.
GYRE is growing revenue faster at 33.4% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 39/100), backed by strong 31.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a biopharmaceutical innovator focused on developing groundbreaking therapies for rare and complex diseases. Leveraging a proprietary platform, the company accelerates the discovery and commercialization of precision treatments tailored to address significant unmet medical needs. With a strong commitment to scientific rigor and patient-centered outcomes, Gyre is strategically positioned to advance its pipeline in gene therapy and precision medicine. Their dedication to research excellence and strategic partnerships highlights their potential for substantial growth in an increasingly competitive biopharmaceutical sector.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?